Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results for the ADC last month. The Boston biotech is ...

Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead ...

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen ...

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers ...

BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (“Pyxis Oncology”) (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation ...